SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.

ABSTRACT:

Background

Patients with epithelial ovarian cancer (EOC) receiving neoadjuvant platinum-based chemotherapy (NACT) who remain ineligible for complete interval cytoreductive surgery (ICS) due to poor chemosensitivity (CA-125 KELIM™ score <1.0) have a poor prognosis (~20% 5-year survival). A weekly dose-dense carboplatin-paclitaxel regimen may improve outcomes in this high-risk subgroup.

Objectives

To demonstrate the superiority of a salvage weekly dose-dense carboplatin-paclitaxel regimen over continuation of the standard 3-weekly regimen in poor-prognosis EOC patients after 3-4 cycles of standard NACT.

Design

SALVOVAR is a pragmatic, open-label, multicenter, international, randomized phase III trial.

Methods and analysis

Patients with stages III-IV high-grade EO

SUBMITTER: Chator C 

PROVIDER: S-EPMC12743993 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature